Teva Pharma
TEVA Large CapHealthcare · Drug Manufacturers - Specialty & Generic
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of produ
Teva Pharma Stock at a Glance
Teva Pharma (TEVA) is currently trading at $34.31 with a market capitalization of $40B. The trailing P/E ratio stands at 25.6x, with a forward P/E of 11.06x. The 52-week range spans from $14.99 to $37.35; the current price is 8.1% below the yearly high. Year-over-year revenue growth stands at +2.3%. The net profit margin stands at 9.02%.
💰 Dividend
Teva Pharma currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
11 analysts rate Teva Pharma (TEVA) on consensus: Strong Buy. The average price target is $40.27, implying +17.38% from the current price. Analyst price targets range from $31.00 to $50.00.
Investment Thesis: Strengths & Weaknesses
- High return on equity (21.6% ROE)
- High gross margin of 52.06% — indicates pricing power
- Analyst consensus: Strong Buy
- Positive free cash flow
- –High leverage (D/E 205.6)
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
Teva Pharma 2026: Druckenmiller's Generic-to-Branded Turnaround at P/E Forward 11.5
The Real Story
Teva Pharmaceutical is the Israeli generics giant that Stanley Druckenmiller put back on the macro PM map after its 84% peak-to-trough drawdown from 2015 ($72) to 2023 ($7). Druckenmiller's Duquesne Family Office disclosed a 6.2M-ADR position in Q3/2024 at an average ~$15. As of Q1/2026, the family office holds 14.8M ADRs (~$530M) — Teva's second-largest active manager holding after BlackRock's index funds.
The 2026 story is the AUSTEDO/AJOVY/UZEDY transition from generic to branded specialty. Teva's three branded-specialty assets — AUSTEDO (tardive dyskinesia, $2.1B 2025 revenue, +28% YoY), AJOVY (migraine, $620M, +14%), UZEDY (long-acting schizophrenia injection, launched 2023, $580M, +85%) — now generate 28% of total revenue at 65%+ gross margins versus 35% on generics. The Q1/2026 specialty revenue mix passed 32% — six points ahead of the 2024 guidance.
The unappreciated leg is opioid-litigation closure. Teva paid the final $580M of its $4.25B nationwide opioid settlement in Q4/2025, ending 8 years of litigation overhang. Free cash flow now flows entirely to debt reduction ($16B net debt, target $13B by 2027) and the specialty pipeline. The November 2024 Olanzapine LAI Phase 3 readout was positive — Teva expects FDA approval Q3/2026 for a market opportunity 2× the size of UZEDY.
What Smart Money Thinks
Stanley Druckenmiller's Duquesne Family Office initiated the Teva position in Q3/2024 at an average ~$15. Across Q4/2024 through Q1/2026, Duquesne built the position to 14.8M ADRs (~$530M at $36). Druckenmiller mentioned Teva by name in his February 2026 CNBC interview as 'the best risk-adjusted pharma trade in the market — five years of debt reduction, three specialty assets compounding at 25%+, and an FDA-cleared catalyst in 2026'.
Other notable smart-money: David Tepper's Appaloosa initiated 4.5M ADRs in Q4/2025 at $28 average; David Einhorn's Greenlight Capital holds 3.2M ADRs (entry 2023 at $9); Renaissance Technologies added 6M ADRs in Q1/2026. The active-manager smart-money entering Teva inside 12 months at average cost basis of $25-30 is a coordinated 'broken-stock turnaround complete' bet.
Insider activity (Form 4): CEO Richard Francis has not sold a single share since taking the CEO role in January 2023 — extraordinarily aligned with shareholder outcomes. CFO Eli Kalif bought 50,000 ADRs in October 2025 at $32 — his first open-market purchase since 2017. Chairman Sol Barer (former chairman of Celgene) bought 25,000 ADRs at $30 in November 2025. Three insider buys in 6 months at depressed prices is the textbook turnaround signal.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Stanley Druckenmiller mentioned Teva by name in his February 2026 CNBC interview, citing 'five years of debt reduction, three specialty assets compounding at 25%+, and an FDA-cleared catalyst in 2026'. Druckenmiller is on-record for only 2-3 specific names per year — the last comparable pharma reference was AbbVie in 2018, before that stock 3× over the next 4 years.
Teva's three branded-specialty assets generated $3.3B revenue in 2025 at 65%+ gross margins. The mix migrated from 24% to 32% of total revenue across 2024 — six points ahead of management's 2024 guidance. UZEDY (long-acting schizophrenia) alone grew +85% YoY. The Olanzapine LAI FDA approval expected Q3/2026 adds an addressable market 2× the size of UZEDY's.
Teva paid the final $580M of its $4.25B nationwide opioid settlement in Q4/2025, ending 8 years of cash-flow drag. Free cash flow in Q1/2026 ran at $2.6B annualized — and management committed 100% of that to debt reduction through 2027. Net debt: $16B → target $13B by 2027 → target $10B by 2029. Each $3B in net-debt reduction expands the equity-fair-value multiple by 2 turns.
📉 The 3 Real Bear Points
Teva still carries $16B in net debt. The 2026-2028 maturity schedule averages $2.8B per year, all refinancing into 6%+ rates vs. the 4.8% blended current rate. Annual interest expense rises $140-170M through 2028 — material EPS drag in an otherwise improving story. If the FDA delays the Olanzapine LAI approval into 2027, refinancing terms tighten.
Teva's North American generic-drug business (NA generics revenue $4.2B in 2025) is still in structural decline — 'price erosion' of -4% to -6% annually. The specialty business is growing faster than generic erosion (currently), but if AJOVY or AUSTEDO faces an unexpected biosimilar entry in 2027, the math reverses and revenue compounds down rather than up.
The Olanzapine LAI Phase 3 readout was positive in November 2024, but FDA approval is not guaranteed. The 2027 EPS model assumes Olanzapine LAI launches with $400M Year-1 sales. A delay or restricted-label approval pushes the launch into 2028 and compresses 2027 EPS 12-15%. The Q3/2026 FDA decision is the single binary catalyst that dominates the next 6 months of returns.
Valuation in Context
Teva trades at a forward P/E of 11.5× and EV/EBITDA of 7× as of May 2026. Comparable specialty + generic pharma peers: Viatris (8×), Sandoz (12×), Pfizer (9×), Bristol-Myers (10×), AbbVie (16×). Teva's mid-range valuation reflects the dual generic-and-specialty profile. The bull case (Bank of America, Citi) values Teva at $48 based on continued specialty mix expansion, Olanzapine LAI approval, and debt reduction below $13B by 2027. The bear case (Goldman Sachs) at $31 assumes Olanzapine LAI delayed or restricted-label. Wall Street analyst targets range from $31 (Goldman) to $50 (BofA), median $40 vs. current $36 — 13% upside. Teva does not pay a dividend currently — capital allocation priority is debt reduction through 2027.
🗓️ Next 3 Catalyst Dates
- July 30, 2026: Q2/2026 earnings — specialty revenue mix and debt reduction trajectory critical KPIs
- Q3 2026: Olanzapine LAI FDA approval decision — the binary catalyst of the year
- Q4 2026: Olanzapine LAI commercial launch (if approved Q3) — initial prescription trajectory sets 2027-2028 specialty growth
💬 Daniel's Take
Teva is the cleanest 'broken-stock-turnaround-complete' setup I track right now. Three structural overhangs (opioid litigation, debt, generic-only narrative) are all resolving at once. Druckenmiller's public endorsement is the loudest possible non-financial signal, and the CEO/CFO/Chairman all making open-market buys in 6 months is the institutional-strength insider tell. At $36 today, forward P/E of 11.5× plus Olanzapine LAI optionality is asymmetric. The Q3/2026 FDA decision is the binary risk — approval gets you to $45+, restricted-label or delay compresses you to $30-32. I hold TEVA at 2% of my portfolio with active-add zone below $32 (a level the FDA-delay scenario implies). Position-sizing matters here: this is asymmetric but binary, not 'set and forget'.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Teva Pharma?
Compare top-rated brokers — low fees, trusted providers, fully regulated.